Core Insights - Qingdao Baiyang Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center focused on brain tumors [2][3] - The center will utilize the ZAP-X radiotherapy robot, which is designed to enhance the precision and safety of brain tumor treatments [2][3] Company Developments - The collaboration marks a significant step for Baiyang Pharmaceutical in promoting the clinical application of high-end radiotherapy equipment and improving access to quality medical resources [3] - Baiyang Pharmaceutical has established a comprehensive industrial chain in the radiotherapy field, covering research and development, production, and operation [3] Industry Context - Brain tumors present a global treatment challenge, with traditional surgical methods often leading to secondary injuries such as nerve damage [2] - The incidence of brain tumors, particularly metastatic brain tumors, has been rising, with over 1.5 million new cases reported annually in China alone [2] - The ZAP-X system, recognized as a revolutionary product in cranial radiotherapy, has been approved for use in 24 countries and regions worldwide, completing over 5,000 clinical treatments [3]
百洋医药将与北京大学国际医院共建精准放疗中心